PBCAR-20A is under clinical development by Precision Biosciences and currently in Phase II for Relapsed Chronic Lymphocytic Leukemia (CLL). According to GlobalData, Phase II drugs for Relapsed Chronic Lymphocytic Leukemia (CLL) have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PBCAR-20A’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PBCAR-20A is under development for the treatment of R/R non-Hodgkin lymphoma, relapsed/refractory mantle cell lymphoma, chronic lymphocytic leukemia and small lymphocytic lymphoma. It is administered as intravenous infusion. The drug candidate is an allogeneic CAR-T therapy. It targets cells expressing CD20. The therapy is developed using electroporation technologies and ARCUS genome-editing technology. It is a genome editing platform derived from a natural genome editing enzyme called homing endonuclease which incorporates Adeno-associated virus (AAV) vector.
Precision Biosciences overview
Precision Biosciences is a biotechnology company, that develops and commercializes gene therapy and cancer immunotherapy. The company focuses its ARCUS technology, a proprietary genome editing platform, which combines specificity and efficacy, on the development of food, fuel, and feed-based products. Precision BioSciences ARCUS technology helps improve genes related to crop quality, yield, and performance traits, and strives to advance food products. The company also applies its ARCUS technology for the development of cell-based immunotherapies to cure genetic diseases. Precision BioSciences genome editing platform is derived from a natural genome editing enzyme, homing endonuclease. The company partners with various pharmaceutical and biotech companies to develop novel therapies for the treatment of cancer. Precision BioSciences is headquartered in Durham, North Carolina, the US.
For a complete picture of PBCAR-20A’s drug-specific PTSR and LoA scores, buy the report here.